Barr Ellison Solicitors – commercial property
Advertisement: Simpsons Creative
Advertisement: partnersand mid banner
Advertisement: Cambridge Network mid banner
Advertisement: CJBS mid banner
Advertisement: Excalibur Healthcare mid banner
Mid banner advertisement: BDO
Advertisement: EBCam mid banner
Advertisement: RSM mid banner
Advertisement: Mogrify mid banner
Advertisement: Kao Data Centre mid banner
Advertisement: HCR Hewitsons recruitment mid banner
Advertisement mid banner S-Tech 1
ARM Innovation Hub
22 October, 2021 - 12:41 By Tony Quested

China deal reaches Crescendo

Crescendo Biologics in Cambridge has clinched a lucrative deal with China and US based Zai Lab, which is quoted on NASDAQ.

The companies are not disclosing figures but Crescendo is eligible for certain development, regulatory and commercial milestones as well as tiered royalties on global sales.

Crescendo is a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics; the windfall follows Zai Lab reporting  positive topline results from a randomized, double-blind, placebo-controlled Phase 1b proof-of-concept study of ZL-1102, an anti-IL-17A targeting Humabody®.

Shanghai-headquartered Zai Lab is a research-based, commercial stage biopharma company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world.

The Phase 1b trial was a first-in-human study to evaluate the safety, pharmacokinetics and efficacy of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque psoriasis (CPP). 

The study recruited 53 patients with CPP, and it is reported that topical therapy with ZL-1102 resulted in clinical improvement in local PASI score, erythema and scaling, target lesion size and responder rates, and that a consistent improvement in patients was seen over time. The safety profile of ZL-1102 was comparable to placebo.

Theodora Harold, chief executive officer at Crescendo, said: “This is a very exciting day for Crescendo. These are the first clinical data from the first patients to be treated with a Humabody and we are very pleased with the topline results reported by our partners at Zai Lab. 

“This is also the first study to demonstrate penetration of a protein biological therapeutic through psoriatic skin resulting in clinical response, illustrating an important point of differentiation of our Humabody platform. We look forward to Zai Lab’s continued progress of ZL1102 into full development, including registrational studies.”

Crescendo previously granted to Zai Lab a worldwide exclusive license to develop and commercialise ZL-1102 for all indications. 

Zai Lab is responsible for conducting all regulatory filings, clinical studies and commercialisation activities, with Crescendo eligible for the payback on the terms outlined above.

Newsletter Subscription

Stay informed of the latest news and features